Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-14), Genetic Analysis AS's 3-1 Month Momentum % is 5.80%.
The industry rank for Genetic Analysis AS's 3-1 Month Momentum % or its related term are showing as below:
FRA:8V8's 3-1 Month Momentum % is ranked better than 55.92% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.23
vs FRA:8V8: 5.80
Genetic Analysis AS (FRA:8V8) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Genetic Analysis AS 3-1 Month Momentum % Related Terms
FRA:8V8 vs TMO, DHR, NTRA: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's 3-1 Month Momentum % falls into.
Genetic Analysis AS (FRA:8V8) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (FRA:8V8) has a 3-1 Month Momentum % of 5.80% as of Sep. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Genetic Analysis AS and its competitors. According to the industry distribution chart, Genetic Analysis AS ranks #93 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 44.1%.
Is Genetic Analysis AS's 3-1 Month Momentum % too high?
Genetic Analysis AS's current 3-1 Month Momentum % is 5.80%. The Medical Diagnostics & Research industry median 3-1 Month Momentum % is 4.23. Genetic Analysis AS's value of 5.80% is 37.1% above this industry median. Based on the distribution chart, Genetic Analysis AS ranks #93 out of 211 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetic Analysis AS has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #93 out of 211 companies for 3-1 Month Momentum %. This puts Genetic Analysis AS in the upper half of its industry. The industry median 3-1 Month Momentum % is 4.23. Genetic Analysis AS's value of 5.80% is 37.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
The median 3-1 Month Momentum % among Medical Diagnostics & Research companies is 4.23, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Analysis AS's current 3-1 Month Momentum % of 5.80% is 37.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median 3-1 Month Momentum % is 4.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current 3-1 Month Momentum % is 5.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current 3-1 Month Momentum % of 5.80%. The stock's GF Value™ is €0.02, compared to a current price of €0.03 — trading 69% above its estimated fair value. The current 3-1 Month Momentum % is 5.80% and 37.1% above the Medical Diagnostics & Research industry median of 4.23. Genetic Analysis AS's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current 3-1 Month Momentum % is 5.80% as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of €0.03 is trading 69% above its estimated GF Value™ of €0.02.
Key valuation signals for FRA:8V8:
3-1 Month Momentum %: 5.80%
GF Value™: €0.02 vs. price of €0.03 (69% above fair value)
Industry Position: 37.1% above the Medical Diagnostics & Research median (#93 of 211)
No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
25GF Score
Get the complete analysis for FRA:8V8
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8V8 has been successfully added to your 
